Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration

Nephrology

Volumn 12, Issue 2, 2007, Pages 120-125

  Pussell, Bruce A ^a   Walker, Rowan ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Epoetin alfa; Erythropoietin; Haemodialysis; Intravenous injection; Subcutaneous injection

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; AUSTRALIA; CHILD; COHORT STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 33947286708     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00761.x     Document Type: Article

References (23)

1. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 1989; 111: 992-1000.
2. Levin NW. Quality of life and hematocrit level. Am. J. Kidney Dis. 1992; 20: 16-20.
3. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br. J. Clin. Pharmacol. 1992; 34: 499-508.
4. McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718-22.
5. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br. J. Clin. Pharmacol. 1990; 29: 709-13.
6. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 439-46.
7. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N. Engl. J. Med. 1998; 339: 578-83.
8. Paganini EP, Eschbach JW, Lazarus JM et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am. J. Kidney Dis. 1995; 26: 331-40.
9. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 2004; 351: 1403-8.
10. De Vos JY, Upsing L. Intravenous administration of epoetin in haemodialysis patients. EDTNA ERCA J. 2003; 29: 156-9.
11. Decaudin B, Lemaitre V, Gautier S, Urbina MA. Epoetin in haemodialysis patients: Impact of change from subcutaneous to intravenous routes of administration. J. Clin. Pharm. Ther. 2004; 29: 325-9.
12. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am. J. Kidney Dis. 2003; 41: 111-24.
13. Fishbane S, Berns J. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337-43.
14. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: A guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509.
15. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur. J. Clin. Pharmacol. 1996; 50: 171-7.
16. Galliford J, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin a in haemodialysis patients requires a major dose increase. Nephrol. Dial. Transplant. 2005; 20: 1956-62.
17. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004; 44: 94-111.
18. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol. Dial. Transplant. 2005; 20 (Suppl. 3): iii3-24.
19. Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Nephrology 2004; 9: 153-60.
20. Reddan DN, Frankenfield DL, Klassen PS et al. Regional variability in anaemia management and haemoglobin in the US. Nephrol. Dial. Transplant. 2003; 18: 147-52.
21. McDonald SP, Russ GR. Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephrology 2003; 8: 42-8.
22. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am. J. Nephrol. 1992; 12: 303-10.
23. Excell L, Marshall M, McDonald S. Haemodialysis p36. ANZDATA Registry Report 2004. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, SA.